AI Revolutionizes Drug Discovery Market by 2032
AI in drug discovery market to skyrocket, reaching USD 11,874.24 million by 2032, with a CAGR of 37.5%.
- Latest
- Trending
AI in drug discovery market to skyrocket, reaching USD 11,874.24 million by 2032, with a CAGR of 37.5%.
Recursion Pharmaceuticals merges with Exscientia to revolutionize drug discovery, bringing new treatments to market more quickly.
Discover Piper Sandler's eight high-quality defensive biotech stocks poised to thrive in volatile markets.
Ventyx Biosciences, Inc. (VTYX) is a high-risk investment with negative net income and high debt ratio, but analysts recommend buying ...
Nocion Therapeutics raises $62M in Series B funding, bringing total funding to $122M. The biopharmaceutical company is developing small molecule ...
Insilico Medicine and University of Toronto collaborate to target "undruggable" cancer genes using AI-designed molecules. AI is revolutionizing drug discovery ...
Pharmaceutical giants Bristol Myers Squibb and Johnson & Johnson invest in Accent Therapeutics, a leading RNA drug developer, contributing to ...
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.